{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:50:38Z","timestamp":1793361038577,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA042014"],"award-info":[{"award-number":["P30CA042014"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41391-025-00936-1","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:23:33Z","timestamp":1738272213000},"page":"887-893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy"],"prefix":"10.1038","volume":"28","author":[{"given":"Georges","family":"Gebrael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1924-8148","authenticated-orcid":false,"given":"Nicolas","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Hage Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0993-1805","authenticated-orcid":false,"given":"Arshit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Chigarira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9521-5436","authenticated-orcid":false,"given":"Ayana","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Tandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6696-7909","authenticated-orcid":false,"given":"Jessica F.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"936_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"936_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"936_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354\u201373.","journal-title":"Endocr Rev"},{"key":"936_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1080\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"936_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet Lond Engl. 2016;387:1163\u201377.","journal-title":"Lancet Lond Engl"},{"key":"936_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686\u2013700.","journal-title":"Lancet Oncol"},{"key":"936_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"936_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"936_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"936_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet Lond Engl. 2022;399:1695\u2013707.","journal-title":"Lancet Lond Engl"},{"key":"936_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"936_CR12","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","volume":"26","author":"KH Stopsack","year":"2020","unstructured":"Stopsack KH, Nandakumar S, Wibmer AG, Haywood S, Weg ES, Barnett ES, et al. Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:3230\u20138.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"936_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","volume":"78","author":"U Swami","year":"2020","unstructured":"Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, et al. Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer. Eur Urol. 2020;78:652\u20136.","journal-title":"Eur Urol"},{"key":"936_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.euo.2021.10.005","volume":"4","author":"K Van der Eecken","year":"2021","unstructured":"Van der Eecken K, Vanwelkenhuyzen J, Deek MP, Tran PT, Warner E, Wyatt AW, et al. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review. Eur Urol Oncol. 2021;4:914\u201323.","journal-title":"Eur Urol Oncol"},{"key":"936_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023\u201331.","journal-title":"Nat Biotechnol"},{"key":"936_CR16","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.26797","volume":"10","author":"N Beaubier","year":"2019","unstructured":"Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019;10:2384\u201396.","journal-title":"Oncotarget"},{"key":"936_CR17","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1128\/MCB.15.5.2536","volume":"15","author":"CL Wu","year":"1995","unstructured":"Wu CL, Zukerberg LR, Ngwu C, Harlow E, Lees JA. In vivo association of E2F and DP family proteins. Mol Cell Biol. 1995;15:2536\u201346.","journal-title":"Mol Cell Biol"},{"key":"936_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrc2399","volume":"8","author":"DL Burkhart","year":"2008","unstructured":"Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671\u201382.","journal-title":"Nat Rev Cancer"},{"key":"936_CR19","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1172\/JCI44239","volume":"120","author":"A Sharma","year":"2010","unstructured":"Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010;120:4478\u201392.","journal-title":"J Clin Invest"},{"key":"936_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/978-3-030-32656-2_13","volume":"1210","author":"DL Burkhart","year":"2019","unstructured":"Burkhart DL, Morel KL, Sheahan AV, Richards ZA, Ellis L. The role of RB in prostate cancer progression. Adv Exp Med Biol. 2019;1210:301\u201318.","journal-title":"Adv Exp Med Biol"},{"key":"936_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","volume":"59","author":"V \u00c1lvarez-Garcia","year":"2019","unstructured":"\u00c1lvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It\u2019s all about diversity. Semin Cancer Biol. 2019;59:66\u201379.","journal-title":"Semin Cancer Biol"},{"key":"936_CR22","first-page":"2856","volume":"17","author":"X Zhou","year":"2019","unstructured":"Zhou X, Yang X, Sun X, Xu X, Li X, Guo Y, et al. Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. Oncol Lett. 2019;17:2856\u201366.","journal-title":"Oncol Lett"},{"key":"936_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78\u201383.","journal-title":"Science"},{"key":"936_CR24","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"936_CR25","doi-asserted-by":"publisher","first-page":"637.e17","DOI":"10.1016\/j.urolonc.2020.03.001","volume":"38","author":"C Nientiedt","year":"2020","unstructured":"Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, et al. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-na\u00efve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol. 2020;38:637.e17\u2013637.e27.","journal-title":"Urol Oncol"},{"key":"936_CR26","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"936_CR27","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","volume":"25","author":"B De Laere","year":"2019","unstructured":"De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:1766\u201373.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"936_CR28","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1038\/sj.onc.1207346","volume":"23","author":"MV Cronauer","year":"2004","unstructured":"Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene. 2004;23:3541\u20139.","journal-title":"Oncogene"},{"key":"936_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76:89\u201397.","journal-title":"Eur Urol"},{"key":"936_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","volume":"25","author":"MG Velez","year":"2022","unstructured":"Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, et al. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:479\u201383.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"936_CR31","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.3390\/cancers14194757","volume":"14","author":"N Jim\u00e9nez","year":"2022","unstructured":"Jim\u00e9nez N, Reig \u00d2, Mar\u00edn-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, et al. Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Cancers. 2022;14:4757.","journal-title":"Cancers"},{"key":"936_CR32","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","volume":"20","author":"PG Corn","year":"2019","unstructured":"Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial. Lancet Oncol. 2019;20:1432\u201343.","journal-title":"Lancet Oncol"},{"key":"936_CR33","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia ELN, Lu JF, Chen HC, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520\u201330.","journal-title":"Clin Cancer Res"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00936-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00936-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:06:28Z","timestamp":1764083188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00936-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00936-1","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA has received honorarium before May 2021 and during his lifetime for consulting to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; and NA\u2019s institution has received research funding during his lifetime from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Meyers Squibb, Calithera, Celldex, Clovis, CRISPR Therapeutics, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. US has been paid for a consulting or advisory role by Astellas, AstraZeneca, Adaptimmune, Exelixis, Gilead, Imvax, Janssen, Pfizer, Seattle Genetics and Sanofi and research funding to institute from Janssen, Exelixis and Astellas\/Seattle Genetics. BLM has received financial compensation as a paid consultant\/advisor to Abbive, Pfizer, AVEO oncology, Janssen, Astellas, Bristol-Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology, Lilly, Sanofi, Telix, Xencor, NCCN and Peloton Therapeutics. Huntsman Cancer Institute has received research funding from Exelixis, Bavarian-Nordic, Clovis and Bristol-Myers Squibb on his behalf.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}